Skip to main content
padlock icon - secure page this page is secure

Monoclonal antibody treatment of colorectal cancer

The full text article is not available for purchase.

The publisher only permits individual articles to be downloaded by subscribers.

Background The recent development of adjuvant monoclonal antibody immunotherapy for patients suffering from colorectal cancer has led to a re-evaluation of the role of these molecules in the treatment of solid tumours. In particular, interest has been directed at identifying appropriate candidates for therapy, evaluating treatment schedules and developing new molecules of therapeutic potential.

Methods This is a review of published data on patients undergoing antibody therapy. In addition, current theories of the mechanism of action of antitumour monoclonal antibodies are presented, along with potential future therapeutic approaches.

Results and conclusion Monoclonal antibody-based adjuvant therapy of colorectal cancer appears to be effective; international multicentre trials continue. The development of new molecules, such as chimaeric antibodies, offers the potential of increased tumour targeting with reduced toxicity. Such molecules may be used alone or in combination with agents such as chemotherapy or cytokines.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Miscellaneous

Affiliations: University of Hull Academic Surgical Unit, Castle Hill Hospital, Cottingham HU16 5JQ, UK

Publication date: November 1, 1997

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more